Thanks Warp. I really liked the dividend idea as a means to fund ambs therapeutics and provide some real shareholder value. Was hoping to hear some pros and cons on that idea from you and other knowledgable folks here. I know biotechs don't normally pay dividends but I think this is different. AMBS didn't set out to become a diagnostics company and I don't believe the new DX company would need all the cash they'll be generating. I don't see them pouring tons of cash into developing neuropro and serapro since I believe GC's preference is to get Lympro into clinical trials and then sell it probably along with the other diagnostics.

Btw, for any dividend investors, Pozen paid a big distribution last Dec. and possibly will pay big future dividends after it's 'safer aspirin' is approved later this year which is almost certain to happen. In April the fda sent POZN a crl citing a manufacturing issue that mgmt believes is easily corrected - it's another Napodano stock worth checking out, imo.